Samsung Medical Centre; Division of Hematology/Oncology
About Samsung Medical Centre; Division of Hematology/Oncology
Samsung Medical Center is a tertiary hospital located in Irwon-Dong of Gangnam-Gu, Seoul, South Korea. SMC is composed of Samsung Seoul Hospital, Kangbook Samsung Hospital, Samsung Changwon Hospital, and Samsung Life Sciences Research Center. SMC was founded on November 9, 1994.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
13
Pfizer
5
BeiGene
2
Genentech, Inc.
2
Samsung Medical Center
2
Daiichi Sankyo, Inc.
1
Epizyme, Inc.
1
Redx Pharma Plc
1
SecuraBio
1
Xynomic Pharmaceuticals, Inc.
1
Clinical Trials at Samsung Medical Centre; Division of Hematology/Oncology
During the past decade, Samsung Medical Centre; Division of Hematology/Oncology conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 15 clinical trials were completed, i.e. on
average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
2003-04-18
2011-04-21
Completed
1,886
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
2007-05-01
2015-03-01
Completed
520
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
2007-07-26
2011-11-30
Terminated
787
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
2009-04-29
2012-02-07
Completed
59
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
2006-06-26
2014-09-22
Completed
417
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
2008-02-12
2018-11-23
Completed
808
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
2009-10-16
2017-01-24
Completed
596
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Samsung Medical Centre; Division of Hematology/Oncology" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Pfizer" with 5 trials
sponsored, "BeiGene" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Samsung Medical Center"
with 2 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Samsung Medical Centre; Division of Hematology/Oncology"
#1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 6 trials.
Clinical Trials Conditions at Samsung Medical Centre; Division of Hematology/Oncology
According to Clinical.Site data, the most researched conditions in "Samsung Medical Centre; Division of Hematology/Oncology" are
"Breast Cancer" (7 trials), "Colorectal Cancer" (2 trials), "Hepatocellular Carcinoma" (2 trials), "Adult T Cell Leukemia/Lymphoma" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Samsung Medical Centre; Division of Hematology/Oncology" in a lesser frequency.
Clinical Trials Intervention Types at Samsung Medical Centre; Division of Hematology/Oncology
Most popular intervention types in "Samsung Medical Centre; Division of Hematology/Oncology" are "Drug" (25 trials), "Other" (3 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (10 trials), "Docetaxel" (6 trials), "Cyclophosphamide" (5 trials), "Pertuzumab" (5 trials) and "Paclitaxel" (4 trials). Other intervention names were less common.
Clinical Trials Genders at Samsung Medical Centre; Division of Hematology/Oncology
The vast majority of trials in "Samsung Medical Centre; Division of Hematology/Oncology" are
25 trials for "All" genders and 4 trials for "Female" genders.
Clinical Trials Status at Samsung Medical Centre; Division of Hematology/Oncology
Currently, there are NaN active trials in "Samsung Medical Centre; Division of Hematology/Oncology".
undefined are not yet recruiting,
4 are recruiting,
6 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 16 completed trials in Samsung Medical Centre; Division of Hematology/Oncology,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Samsung Medical Centre; Division of Hematology/Oncology, 0 "Phase 1"
clinical trials were conducted, 10 "Phase 2" clinical
trials and 13 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".